“Glucagon-like peptide-1 (GLP-1) receptor agonists may be useful for secondary prevention of atrial fibrillation (AF) in patients with obesity and type 2 diabetes, new results from the observational TRANSFORM-AF study suggest. Patients with active AF who initiated a GLP-1 receptor agonist had a lower risk of AF-related events over several years of follow-up compared with those taking other medications for their diabetes (HR 0.87; 95% CI 0.68-0.96), researchers reported here at Heart Rhythm 2025. This was seen despite only modest differences in weight loss between groups, raising questions about potential pleiotropic effects of the GLP-1 drugs.”From TCTMD.